Financial Highlights & Recent Developments
- Research and development expense was
$554 thousand , a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines. - Through
March 31, 2026 , the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries acrossthe United States ,Europe andAsia .
“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while continuing to invest selectively in the highest-return areas of the business. As a result, we are better positioned to operate efficiently in a dynamic macro environment. At the same time, our sales team is advancing a healthy sales pipeline supported by strong lead generation and ongoing customer engagement across key markets. Our deployments to date support these efforts with real-world demonstration of our solution capabilities and compelling data affirming the unique benefits of mass spectrometry technology in industrial, safety and trace detection applications. Looking ahead, we will continue to balance rigorous expense control with strategic investments to help convert pipeline opportunities into revenue growth”, said
About
- 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening.
- AgLAB designs process analyzers tailored to the processing of agriculture products.
- Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
EN-SCAN, Inc. delivers portable, ruggedized environmental GC-MS for on-site testing of air, water and soil.
Forward-Looking Statements
This press release contains “forward-looking statements” that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company’s use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company’s
Company Contact:
Interim Chief Financial Officer,
(512) 485-9530
Investor Contact:
Managing Director,
(214) 597-8200 mkreps@darrowir.com
Financial tables follow
| ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 343 | $ | 534 | $ | 787 | $ | 829 | ||||||||
| Cost of revenue | 276 | 297 | 525 | 428 | ||||||||||||
| Gross profit | 67 | 237 | 262 | 401 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 2,085 | 2,115 | 5,941 | 5,842 | ||||||||||||
| Research and development | 1,435 | 1,989 | 5,211 | 6,375 | ||||||||||||
| Total operating expenses | 3,520 | 4,104 | 11,152 | 12,217 | ||||||||||||
| Loss from operations | (3,453 | ) | (3,867 | ) | (10,890 | ) | (11,816 | ) | ||||||||
| Other income and expense, net | (315 | ) | 234 | (271 | ) | 896 | ||||||||||
| Loss from operations before income taxes | (3,768 | ) | (3,633 | ) | (11,161 | ) | (10,920 | ) | ||||||||
| Net loss | $ | (3,768 | ) | $ | (3,633 | ) | $ | (11,161 | ) | $ | (10,920 | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic and diluted | 1,677 | 1,665 | 1,676 | 1,663 | ||||||||||||
| Basic and diluted net loss per common share: | ||||||||||||||||
| Net loss per common share | $ | (2.25 | ) | $ | (2.18 | ) | $ | (6.66 | ) | $ | (6.57 | ) | ||||
| Other comprehensive loss, net of tax: | ||||||||||||||||
| Net loss | $ | (3,768 | ) | $ | (3,633 | ) | $ | (11,161 | ) | $ | (10,920 | ) | ||||
| Available-for-sale securities: | ||||||||||||||||
| Net unrealized gain (loss) | 159 | 139 | 476 | 236 | ||||||||||||
| Total comprehensive loss | $ | (3,609 | ) | $ | (3,494 | ) | $ | (10,685 | ) | $ | (10,684 | ) | ||||
| ASTROTECH CORPORATION AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share and per share data) | ||||||||
| 2026 | 2025 | |||||||
| (Unaudited) | (Note) | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 2,679 | $ | 3,100 | ||||
| Short-term investments | 3,903 | 15,108 | ||||||
| Accounts receivable | 504 | 485 | ||||||
| Inventory, net: | ||||||||
| Raw materials | 3,019 | 2,194 | ||||||
| Work-in-process | 531 | 425 | ||||||
| Finished goods | 310 | 310 | ||||||
| Prepaid expenses and other current assets | 383 | 353 | ||||||
| Total current assets | 11,329 | 21,975 | ||||||
| Property and equipment, net | 2,573 | 2,395 | ||||||
| Intangible asset, net | 50 | 48 | ||||||
| Operating lease right-of-use assets, net | 1,906 | 2,225 | ||||||
| Other assets, net | 315 | 346 | ||||||
| Total assets | $ | 16,173 | $ | 26,989 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 234 | $ | 1,066 | ||||
| Payroll related accruals | 461 | 529 | ||||||
| Accrued expenses and other liabilities | 865 | 451 | ||||||
| Lease liabilities, current | 275 | 405 | ||||||
| Total current liabilities | 1,835 | 2,451 | ||||||
| Accrued expenses and other liabilities, net of current portion | 79 | 164 | ||||||
| Lease liabilities, net of current portion | 2,104 | 2,274 | ||||||
| Total liabilities | 4,018 | 4,889 | ||||||
| Commitments and contingencies (Note 14) | ||||||||
| Stockholders’ equity | ||||||||
| Convertible preferred stock, | — | — | ||||||
| Common stock, | 190,643 | 190,643 | ||||||
| (119 | ) | (119 | ) | |||||
| Additional paid-in capital | 84,050 | 83,310 | ||||||
| Accumulated deficit | (262,030 | ) | (250,870 | ) | ||||
| Accumulated other comprehensive loss | (389 | ) | (864 | ) | ||||
| Total stockholders’ equity | 12,155 | 22,100 | ||||||
| Total liabilities and stockholders’ equity | $ | 16,173 | $ | 26,989 | ||||
Note: The balance sheet at June 30, 2025 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by
Source: